EUVIMEDOpdag EUVIMED
KohortenstudieStudienprotokollOpen access

Investigation of Vaccine-Induced Immune Response After Vaccination Against Respiratory Viruses in Immunocompromised Patients With or Without Hemato-Oncological Diseases (RESPONSE): Protocol for a Prospective Cohort Study

Eloísa Felipe Fumero iD, Jannik Stemler iD, Rosanne Sprute iD, Katja M Sauer iD, Henning Gruell iD, Christoph Kreer iD, Florian Klein iD, Sebastian J Theobald iD, Jan Rybniker iD, Oliver A Cornely iD, Lara Kappes iD, Louise M Cremer iD and 1 more

JMIR Research Protocols · 2026-07-23 · 15 · e88520

DOI: 10.2196/88520 ↗

At a glance

Kohortenstudie in JMIR Research Protocols, published online on 2026-07-23. Written by Eloísa Felipe Fumero and 12 co-authors. Institution: Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD) and Excellence Center for Medical Mycolo…. Major MEDLINE topics: Immunocompromised Host, Hematologic Neoplasms, COVID-19, COVID-19 Vaccines. 27 references. The full text is freely available in PubMed Central.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Infections with respiratory viruses such as SARS-CoV-2 and influenza are significant international public health concerns. While patients with cancer remain the most vulnerable group, they show poor vaccine response in general. Immunological data in this population are limited and mainly focus on serological parameters. However, in these patients, cellular, and especially T-cell, responses often seem to be induced more reliably than humoral responses.

Objective

To gain further insights into vaccine-induced immunity, the RESPONSE study will analyze the effect of early and late booster vaccination on humoral and cellular responses, with special focus on T cell–induced immune responses. In addition, we aim to investigate factors influencing humoral and cellular vaccine-induced immunity in patients with hematological and oncological malignancies, including state of disease, treatment, and demographic factors.

Methods

Humoral immune responses will be assessed by measuring binding and neutralizing antibodies using standardized assays. Cellular immunity will be evaluated using functional assays such as flow cytometry and FluoroSpot, as well as in-depth analyses using additional exploratory assays as appropriate. Immune responses will be correlated with clinical parameters, including disease status, treatment, and demographic factors.

Results

This study was initiated following ethics approval and is currently recruiting participants. Enrollment commenced on March 25, 2025, and is ongoing, whereas biosample collection and follow-up visits are nearing completion for most participants. Final data cleaning, dataset integration, and statistical analyses of adaptive immune responses are planned from the third quarter of 2026 onward.

Conclusions

This study intends to lay a foundation for a structured translational research platform on vaccination to aim for best protection from infection by different respiratory pathogens. Long-term objectives are reaching best possible protection from vaccine-preventable disease with a first focus on influenza infection. In addition, we plan to investigate vaccine-induced immune responses to the recently approved respiratory syncytial virus vaccine using this platform and possibly extend this to further vaccines in the future. Urgent questions, such as the influence of different targeted therapies on vaccine immune response, will be part of these projects. Trial Registration ClinicalTrials.gov NCT06612515; https://clinicaltrials.gov/study/NCT06612515 International Registered Report Identifier (IRRID) DERR1-10.2196/88520

Subjects

MeSH terms (MEDLINE)

Immunocompromised HostHematologic NeoplasmsCOVID-19COVID-19 VaccinesHumansProspective StudiesImmunity, HumoralImmunity, CellularVaccinationFemaleSARS-CoV-2Antibodies, ViralMale

Author keywords

cellular immune responsehematological patientshumoral immune responseimmunocompromised hostrespiratory viral infectionsvaccination

Substances

COVID-19 VaccinesAntibodies, Viral

Authors and institutions

  • Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD) and Excellence Center for Medical Mycology (ECMM), University Hospital Cologne, Cologne, Germany.
  • Institute of Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany.
  • German Center for Infection Research (DZIF), Partner Site Bonn-Cologne, Cologne, Germany.
  • Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
  • Clinical Trials Centre Cologne (ZKS Köln), University of Cologne, Cologne, Germany.

ORCID profiles: Eloísa Felipe Fumero, Jannik Stemler, Rosanne Sprute, Katja M Sauer, Henning Gruell, Christoph Kreer, Florian Klein, Sebastian J Theobald, Jan Rybniker, Oliver A Cornely, Lara Kappes, Louise M Cremer, Sibylle C Mellinghoff

Cite

APA

Felipe Fumero, E., Stemler, J., Sprute, R., Sauer, K. M., Gruell, H., Kreer, C., Klein, F., Theobald, S. J., Rybniker, J., Cornely, O. A., Kappes, L., Cremer, L. M., & Mellinghoff, S. C. (2026). Investigation of Vaccine-Induced Immune Response After Vaccination Against Respiratory Viruses in Immunocompromised Patients With or Without Hemato-Oncological Diseases (RESPONSE): Protocol for a Prospective Cohort Study. JMIR Research Protocols, 15, e88520. https://doi.org/10.2196/88520

Vancouver

Felipe Fumero E, Stemler J, Sprute R, Sauer KM, Gruell H, Kreer C, et al. Investigation of Vaccine-Induced Immune Response After Vaccination Against Respiratory Viruses in Immunocompromised Patients With or Without Hemato-Oncological Diseases (RESPONSE): Protocol for a Prospective Cohort Study. JMIR Research Protocols. 2026;15:e88520. doi:10.2196/88520

BibTeX
@article{FelipeFumero2026,
  author = {Felipe Fumero, Eloísa and Stemler, Jannik and Sprute, Rosanne and Sauer, Katja M and Gruell, Henning and Kreer, Christoph and Klein, Florian and Theobald, Sebastian J and Rybniker, Jan and Cornely, Oliver A and Kappes, Lara and Cremer, Louise M and Mellinghoff, Sibylle C},
  title = {Investigation of Vaccine-Induced Immune Response After Vaccination Against Respiratory Viruses in Immunocompromised Patients With or Without Hemato-Oncological Diseases (RESPONSE): Protocol for a Prospective Cohort Study},
  journal = {JMIR Research Protocols},
  year = {2026},
  volume = {15},
  pages = {e88520},
  doi = {10.2196/88520}
}
Start for free →